Chimerix Chooses Merck As HIV Partner, Keeps Broad-Spectrum Antiviral

 
• By Paul Bonanos

The North Carolina-based start-up strikes a global deal for a Phase I HIV drug, which will allow it to fund late-stage trials on another lipid-antiviral conjugate.

Chimerix Inc. has chosen Merck & Co. Inc. as its global partner for the Phase I HIV drug CMX157, allowing the start-up to focus on a crucial Phase III trial for a late-stage antiviral compound.

Merck will pay $17.5 million up-front for worldwide rights to ’157, in a deal that could be worth $151 million...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

More from Pink Sheet